Johnson & Johnson is under investigation by Pomerantz LLP for potential securities fraud related to its Q3 2026 financial results. The company reported a net earnings of $210 million, significantly impacted by large charges from talc litigation settlements and weaker-than-expected revenue growth in its MedTech segment, especially due to challenges in China and the Middle East. Following the earnings report, J&J's stock fell 5.73%. The investigation aims to determine if J&J and its executives engaged in unlawful business practices, which could affect investor confidence and future legal outcomes.
Johnson & Johnson holds a substantial market cap of $675.03 billion on Pluang as of Nov 12, 2026, 22:52 WIB, with a dividend yield of 1.91%. Despite the recent investigation news and a reported 5.73% stock drop, JNJ's price on Pluang has risen by 1.24% to USD 283.89, supported by a strong buy interest at 83% of order activity. The stock sees a typical hold time of 130 days, indicating steady investor engagement.
Pomerantz LLP is investigating Johnson & Johnson for potential securities fraud following the company's Q3 2026 report, which showed a net earnings drop to $210 million due to large talc litigation charges and weak MedTech revenue growth. The investi...
A $300,000 investment split equally among Duke Energy, Philip Morris, and Johnson & Johnson generates about $8,590 in annual passive income with a blended yield of 2.86%. Duke Energy offers the highest yield at 3.39%, followed closely by Philip Morri...
Johnson & Johnson announced that CAPLYTA (lumateperone) met primary and key secondary endpoints in a Phase 3 study for treating manic episodes in bipolar I disorder, showing significant symptom improvement as early as Day 3 and sustained through Week...
Following the 2026 midterm elections resulting in a divided U.S. government, four dividend-paying blue-chip stocks—Duke Energy, Procter & Gamble, Johnson & Johnson, and JPMorgan Chase—are highlighted for their resilience amid legislative gridlock. Th...
Johnson & Johnson announced promising Phase 1 results for a novel immunotherapy combining pasritamig and JNJ-9401, targeting two prostate cancer proteins to activate T cells. In the trial, 73% of patients saw PSA levels drop by at least 50%, with nea...
